The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma

Gut

Volumn 57, Issue 2, 2008, Pages 243-251

  Hellerbrand, Claus ^a   Amann, T ^a   Schlegel, J ^a   Wild, P ^b   Bataille, F ^b   Spruss, T ^a   Hartmann, A ^a   Bosserhoff, A K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1; KI 67 ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL CLONE; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MELANOMA INHIBITORY ACTIVITY 2 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HEPATOCYTE NUCLEAR FACTOR 1; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 38549175151     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.129544     Document Type: Article

References (24)

1. El Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-S34.
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
3. Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-19.
4. Bosserhoff AK, Moser M, Scholmerich J, et al. Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. J Biol Chem 2003;278:15225-31.
5. Bosserhoff AK, Moser M, Buettner R. Characterization and expression pattern of the novel MIA homolog TANGO. Gene Expr Patterns 2004;4:473-9.
6. Stoll R, Renner C, Zweckstetter M, et al. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J 2001;20:340-9.
7. Bosserhoff AK. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res 2005;18:411-16.
8. Bosserhoff AK, Buettner R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol 2002;17:289-300.
9. Hellerbrand C, Bataille F, Schlegel J, et al. In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int 2005;25:357-66.
10. Weiss TS, Jahn B, Cetto M, et al. Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif 2002;35:257-67.
11. Muhlbauer M, Fleck M, Schutz C, et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 2006;45:520-8.
12. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11:4415-29.
13. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med 2004;97:377-89.
14. Rothhammer T, Bataille F, Spruss T, et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 2006, Dec 18; [Epub ahead of print].
15. Hellerbrand C, Muhlbauer M, Wallner S, et al. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 2006;27:64-72.
16. Schuierer MM, Bataille F, Weiss TS, et al. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006;16:451-6.
17. Kuphal S, Wallner S, Schimanski CC, et al. Expression of Hugl-1 is strongly reduced in malignant melanoma. Oncogene 2006;25:103-10.
18. Kiessling S, Muller-Newen G, Leeb SN, et al. Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem 2004;279:10304-15.
19. Kalkuhl A, Kaestner K, Buchmann A, et al. Expression of hepatocyte-enriched nuclear transcription factors in mouse liver tumours. Carcinogenesis 1996;17:609-12.
20. Ishiyama T, Kano J, Minami Y, et al. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci 2003;94:757-63.
21. Xu L, Hui L, Wang S, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 2001;61:3176-81.
22. Pontoglio M, Barra J, Hadchouel M, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996;84:575-85.
23. Lee YH, Sauer B, Gonzalez FJ. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1 alpha knockout mouse. Mol Cell Biol 1998;18:3059-68.
24. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002;32:312- 15.